The Report
OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and
Forecasts to 2025 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
MarketResearchReports.biz
has added a new market study to its repository, titled “Opportunity
Analyzer: Myelofibrosis
- Opportunity Analysis And Forecasts To 2025.” Myelofibrosis (MF)
is a rare and serious blood disorder, which is characterized by bone
marrow fibrosis. It hampers the body’s normal production of blood
cells. At present, there is just one approved drug, Incyte/Novartis
Jakafi (ruxolitinib), for the treatment of MF, and other conventional
therapies leveraged to treat MF are off-label. Some of the off-label
therapies are cytoreductive drug, androgen therapies,
erythropoiesis-stimulating agents, immunomodulatory imide drugs, and
anti-fibrotic agents.
However,
none of the available drugs can cure. The only potentially curative
intervention is allogeneic stem cell transplant (allo-SCT) and it is
available to a very small percentage of eligible patients because of
the high risk of morbidity and mortality. Hence, there is a
significant unmet need for the treatment of MF.
The
report brings to the fore the substantial dearth of novel drugs to
treat myelofibrosis, both to lessen complications pertaining to MF
and to reverse the course of the disease. It sheds light on the
opportunities for new market players in the market whose value is
likely to increase twofold from 2015 to 2025. Some of the factors
that will foster the growth in the market for myelofibrosis drugs are
the unveiling of pipeline drugs – particularly second-line
treatments for patients who are refractory to Jakafi, growing
instances of the disorder, and a surge in the use of drugs for
splenomegaly, and constitutional symptoms in the European Union and
Japan.
High
cost involved in treatment of myelofibrosis has crimped its market
growth so far and the unmet needs are expected to be only partly
resolved by the prominent pipeline drugs. Further, at present there
are no approved or major pipeline drugs for anemia associated with
myelofibrosis.
Any
drug that can address this need will most likely be a big hit in the
market.
The
report provides a thorough overview of MF that includes epidemiology,
etiology, pathophysiology, symptoms, diagnosis, treatment guidelines,
and disease management. It uncovers the annual revenue in the MF
therapeutics market and presents crucial figures related to average
cost of therapy, treatment usage, and future revenue. It presents an
assessment of the competitive landscape, characterization of the
market, unmet needs, and clinical trial mapping.
View Press Release @
http://www.marketresearchreports.biz/pressrelease/3743
From
a geographical standpoint, North America accounts for a maximum share
in the global myelofibrosis market in terms of value. This is because
of the rising awareness and high occurrence of the malady, greater
percentage of income devoted to healthcare, and favorable
reimbursement policies. In the years ahead, Asia Pacific is slated to
account for a substantial share in the market due to a large elderly
population base, rising fortunes of the people and bettering
healthcare facilities.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment